Non-alcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue SUPPL 1, 2013, Pages 68-76

  Schuppan, Detlef ^a   Schattenberg, Jörn M ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Diabetes; DPP 4; Fibrosis; FXR; GLP 1; Lifestyle; Metabolic syndrome; Microbiome; NASH

Indexed keywords

ADIPOCYTOKINE; BEZAFIBRATE; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; HUMORAL ANTIBODY; LIRAGLUTIDE; NIVOCASAN; OBETICHOLIC ACID; PIOGLITAZONE; PROBIOTIC AGENT; ROSIGLITAZONE; TUROFEXORATE ISOPROPYL; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; DISEASE COURSE; END STAGE LIVER DISEASE; EXERCISE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; MACROPHAGE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDENTARY LIFESTYLE; SIDE EFFECT; STEM CELL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84880419922     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12212     Document Type: Review

References (92)

1. Alberti KG, Eckel RH, Grundy SM etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
2. Almeda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann. Hepatol. 2009; 8 (Suppl. 1): S18-24.
3. Williams CD, Stengel J, Asike MI etal. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
4. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
5. Younossi ZM, Stepanova M, Negro F etal. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91: 319-327.
6. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol. 2009; 50: 1029-1034.
7. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 163-172.
8. Das K, Das K, Mukherjee PS etal. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 1593-1602.
9. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia-as common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013; doi: 10.1038/nrgastro.2013.34.
10. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 2009; 13: 511-531.
11. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 2009; 8 (Suppl. 1): S4-S8.
12. Wong VW, Wong GL, Choi PC etal. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.
13. Bedogni G, Miglioli L, Masutti F etal. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-1391.
14. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr. Pharm. Des. 2013 Feb 4 [Epub ahead of print]. doi: 10.2174/13816128113199990336.
15. Argo CK, Northup PG, Al Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 371-379.
16. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
17. Romeo S, Kozlitina J, Xing C etal. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008; 40: 1461-1465.
18. Pirola CJ, Fernandez GT, Burgueno AL etal. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2012. DOI: 10.1136/gutjnl-2012-302962.
19. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 2008; 49: 608-612.
20. Ekstedt M, Franzen LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
21. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 363: 1341-1350.
22. Stefan N, Kantartzis K, Machann J etal. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 2008; 168: 1609-1616.
23. White DL, Kanwal F, El Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 2012; 10: 1342-1359.
24. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
25. Savard C, Tartaglione EV, Kuver R etal. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 2013; 57: 81-92.
26. Neuschwander-Tetri BA, Wang DQ. Excess cholesterol and fat in the diet: a dangerous liaison for energy expenditure and the liver. Hepatology 2013; 57: 7-9.
27. Kalaany NY, Gauthier KC, Zavacki AM etal. LXRs regulate the balance between fat storage and oxidation. Cell Metab. 2005; 1: 231-244.
28. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788.
29. Neuschwander-Tetri BA, Ford DA, Acharya S etal. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012; 47: 941-950.
30. Abdelmalek MF, Suzuki A, Guy C etal. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1961-1971.
31. Abdelmalek MF, Lazo M, Horska A etal. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 2012; 56: 952-960.
32. Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009; 14: 1459-1471.
33. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009; 50: 1094-1104.
34. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 2011; 22: 699-711.
35. Ye D, Li FY, Lam KS etal. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012; 61: 1058-1067.
36. Teratani T, Tomita K, Suzuki T etal. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012; 142: 152-164.
37. Machado MV, Cortez-Pinto H. No need for a large belly to have NASH. J. Hepatol. 2011; 54: 1090-1093.
38. Rabot S, Membrez M, Bruneau A etal. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010; 24: 4948-4959.
39. Zhu L, Baker SS, Gill C etal. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609.
40. Miele L, Valenza V, La Torre G etal. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
41. Henao-Mejia J, Elinav E, Jin C etal. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
42. Vrieze A, Van Nood E, Holleman F etal. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.
43. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
44. Dubuquoy C, Robichon C, Lasnier F etal. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J. Hepatol. 2011; 55: 145-153.
45. Dubuquoy C, Burnol AF, Moldes M. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? Clin. Res. Hepatol. Gastroenterol. 2013; 37: 30-35.
46. Kumari M, Schoiswohl G, Chitraju C etal. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 2012; 15: 691-702.
47. Li JZ, Huang Y, Karaman R etal. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Invest. 2012; 122: 4130-4144.
48. Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr. Opin. Lipidol. 2011; 22: 479-488.
49. Ratziu V, Charlotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
50. Shen J, Chan HL, Wong GL etal. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J. Hepatol. 2012; 56: 1363-1370.
51. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447.
52. Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin. Liver Dis. 2012; 16: 567-585.
53. Kornek M, Lynch M, Mehta SH etal. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 2012; 143: 448-458.
54. Goodpaster BH, Delany JP, Otto AD etal. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 2010; 304: 1795-1802.
55. Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig. Dis. 2010; 28: 267-273.
56. Fealy CE, Haus JM, Solomon TP etal. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J. Appl. Physiol. 2012; 113: 1-6.
57. Koh-Banerjee P, Chu NF, Spiegelman D etal. Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. Am. J. Clin. Nutr. 2003; 78: 719-727.
58. Schattenberg JM, Singh R, Wang Y etal. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006; 43: 163-172.
59. MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. Curr. Opin. Drug Discov. Devel. 2010; 13: 568-576.
60. Hatting M, Zhao G, Schumacher F etal. Hepatocyte caspase-8 is an essential modulator of steatohepatitis in mice. Hepatology 2013 (in press). DOI: 10.1002/hep.26271.
61. Anstee QM, Concas D, Kudo H etal. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 2010; 53: 542-550.
62. Ratziu V, Sheikh MY, Sanyal AJ etal. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55: 419-428.
63. Robson SC, Schuppan D. Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J. Hepatol. 2010; 52: 941-943.
64. Imarisio C, Alchera E, Sutti S etal. Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats. Clin. Sci. (Lond) 2012; 123: 323-332.
65. Peng Z, Borea PA, Varani K etal. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J. Clin. Invest. 2009; 119: 582-594.
66. Stensel D. Exercise, appetite and appetite-regulating hormones: implications for food intake and weight control. Ann. Nutr. Metab. 2010; 57 (Suppl. 2): 36-42.
67. Massa F, Mancini G, Schmidt H etal. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J. Neurosci. 2010; 30: 6273-6281.
68. Holst JJ. Incretin hormones and the satiation signal. Int. J. Obes. (Lond) 2013; DOI: 10.1038/ijo.2012.208.
69. Balaban YH, Korkusuz P, Simsek H etal. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann. Hepatol. 2007; 6: 242-250.
70. Miura K, Kitahara Y, Yamagishi S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm. Metab. Res. 2010; 42: 731-735.
71. Kern M, Kloting N, Niessen HG etal. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS ONE 2012; 7: e38744.
72. Mells JE, Fu PP, Sharma S etal. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G225-235.
73. Trevaskis JL, Griffin PS, Wittmer C etal. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G762-772.
74. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE 2011; 6: e25269.
75. Nagasawa T, Inada Y, Nakano S etal. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 2006; 536: 182-191.
76. Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. Peroxisome proliferator-activated receptor-alpha agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2012; 27: 341-350.
77. Serrano-Marco L, Barroso E, El K I etal. The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia 2012; 55: 743-751.
78. Ratziu V, Giral P, Jacqueminet S etal. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008; 135: 100-110.
79. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010; 362: 1675-1685.
80. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34: 2008-2014.
81. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur. J. Pharmacol. 2009; 618: 98-104.
82. Teixeira-Clerc F, Julien B, Grenard P etal. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 2006; 12: 671-676.
83. Chavez-Tapia NC, Tellez-Avila FI, Bedogni G, Croce LS, Masutti F, Tiribelli C. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. BMC Gastroenterol. 2009; 9: 75.
84. Janero DR, Lindsley L, Vemuri VK, Makriyannis A. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opin. Drug Discov. 2011; 6: 995-1025.
85. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005; 365: 1363-1364.
86. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today 2012; 17: 988-997.
87. Hollman DA, Milona A, van Erpecum KJ, van Mil SW. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim. Biophys. Acta 2012; 1821: 1443-1452.
88. Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 380-388.
89. Mencarelli A, Cipriani S, Renga B etal. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE 2012; 7: e45425.
90. Wagnerberger S, Spruss A, Kanuri G etal. Lactobaccilus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J. Nutr. Biochem. 2013; 24: 531-538.
91. Wong VW, Won GL, Chim AM etal. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol. 2013; 12: 256-262.
92. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012; 32: 701-711.